• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search

Impact of RBX2660 on the Intestinal Microbiota of Patients with Recurrent Clostridium difficile Infection Enrolled in the Randomized, Placebo-Controlled PUNCH CD 2 Trial

Courtney Jones, BS; Bill Shannon, PhD, MBA; Sharina Carter, BS

Download this poster (1.2 MB)
Download the abstract (43 KB)

Infectious Diseases Week (ID Week)
October 26-30, 2016, New Orleans, LA

Background

  • Perturbation of the intestinal microbiota, primarily by antibiotics, is a risk factor for Clostridium difficile infection (CDI).
  • Restoration of a variable intestinal microbiota protects against recurrence of CDI.
  • RBX2660 is a microbiota-based drug under study for the prevention of recurrent CDI.
  • We evaluated the impact of RBX2660 treatment on the intestinal microbiota of patients enrolled in the PUNCH CD 2 trial, a multicenter, randomized, double-blinded, placebo controlled phase 2b study.

Methods

  • Patients in the 3-arm PUNCH CD 2 trial were randomized 1:1:1 to receive either: 2 doses of RBX2660 (Group A); 2 doses of placebo (Group B); or 1 dose of RBX2660 and 1 dose of placebo (Group C). Success was defined as the absence of Clostridium difficile -associated diarrhea at 8 weeks following completion of the last treatment.
  • Failure was defined as recurrence of CDI symptoms; a positive stool test; a need for CDI retreatment; and no other cause for CDI symptoms within 8 weeks.
  • Longitudinal 16s rRNA analysis using the Illumina MiSeq platform was performed on a total of 120 stool samples from patients in the 3 arms of the study (Group A: n=23; Group B: n=22; Group C: n= 22) at baseline, 7 days and 30 days after the second blinded dose.
  • The variable region V4 was targeted to identify the operational taxonomic units (OTUs) in each sample.

Results

  • At baseline, the microbiota profiles were similar across all samples.
  • OTU analysis demonstrated higher diversity between baseline and follow-up time points for all patients who responded successfully to their assigned treatment.
  • The higher diversity at follow-up points was also true for placebo responders (12 patients in Group B who received two doses of placebo and did not experience recurrent CDI symptoms prior to 8-week follow-up).
  • Specifically, successful Group A patients had an increase in Akkermansia and Bacteroides from baseline; successful Group B and C patients had a decreased abundance of Enterobacter (Figures 1-3).
  • Of the three groups of patients, those in Group A (two doses of active treatment) showed the greatest increase in bacterial diversity (number of OTUs) and abundance of taxa between baseline and all follow-up points (Figure 4).

Conclusions

  • In this randomized, placebo-controlled study of RBX2660 for recurrent CDI, 16s rRNA analysis found that patients who succeeded with their assigned therapy had a more diverse intestinal microbiota at 7 and 30 days compared with baseline.

Microbiota Restoration Therapy Abstracts, Microbiota Restoration Therapy Posters Abstracts, Posters

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT